• Acetylcholine Chloride in Gut–Brain Assays

  2026-09-29

  Use Acetylcholine Chloride as a defined cholinergic stimulus to separate receptor-level responses from microbiota- and vagus-dependent effects. This workflow translates recent gut–brain findings into practical assay design, concentration planning, controls, and troubleshooting.

• FTSJ3 Loss, R-Loops, and Lung Cancer Chemosensitivity

  2026-09-29

  The reference study identifies FTSJ3 as a regulator of R-loop homeostasis and genomic stability in lung cancer cells. Its depletion increases R-loop-associated DNA damage and sensitizes tumors to cisplatin, supporting FTSJ3 as a potential biomarker of chemotherapy response and a therapeutic vulnerability.

• Z-VAD-FMK: Mechanism, Evidence, and Workflow

  2026-09-28

  Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor used to test caspase dependence in apoptosis models. Its strongest use is as a mechanistic perturbation, not as proof that all forms of cell death have been prevented.

• AG-221: From 2-HG Suppression to Causal Biology

  2026-09-28

  AG-221 (Enasidenib) can reveal more than whether mutant IDH2 activity is inhibited. This article explains how to interpret 2-hydroxyglutarate reduction alongside metabolic adaptation, CD44 biology, and leukemia-cell differentiation in acute myeloid leukemia research.

• Ibrexafungerp Workflows for Candida Research

  2026-09-27

  Ibrexafungerp (MK 3118) offers a practical way to investigate Candida isolates that respond poorly to azoles or echinocandins, with in vitro activity and delayed-start efficacy reported in a mouse model of invasive candidiasis. This guide translates those findings into susceptibility-testing, model-selection, and troubleshooting decisions while separating published conditions from suggested assay adaptations.

• Cy5 TSA: From Signal Gain to Spatial Insight

  2026-09-26

  The Cy5 TSA Fluorescence System Kit boosts localized fluorescence for immunohistochemistry, immunocytochemistry, and in situ hybridization. This article explains how to choose TSA within a spatial assay strategy, drawing a practical distinction between brighter target detection and proteome-wide spatial profiling.

• Ibrexafungerp Against Echinocandin-Resistant Candida

  2026-09-25

  A clinical-isolate study tested ibrexafungerp against 192 echinocandin-resistant Candida isolates and compared susceptibility patterns across FKS hotspot mutations. The results show that activity varies with mutation position, underscoring both the potential and the limits of inferring cross-resistance from target-level mechanisms.

• Tetracycline: Workflows for Selection and Assay Control

  2026-09-25

  Tetracycline is useful for bacterial selection and ribosomal-function experiments, but its antibiotic activity should not be mistaken for a direct way to probe HBV signaling in hepatocytes. This guide turns its mechanism and handling properties into practical workflows, then connects them carefully to research on QRICH1, ER stress, and HMGB1.

• Anti-HMGB1 Rabbit Monoclonal Antibody Guide

  2026-09-24

  Anti-HMGB1 Rabbit Monoclonal Antibody (MA3057) supports detection of HMGB1 in human, mouse, and rat samples by Western blot, immunohistochemistry, and flow cytometry. Use it for research workflows with assay-specific optimization; it is not intended for diagnostic, medical, or therapeutic use.

• Protease Inhibitor Cocktail for Skin-Model Assays

  2026-09-24

  Learn how Protease Inhibitor Cocktail EDTA-Free can strengthen the post-collection evidence behind skin-model research. This article connects a recent melatonin-loaded hydrogel study to practical assay decisions while distinguishing sample preservation from biological mechanism.

• SmD2 Acetylation Shapes PARP Sensitivity in HCC

  2026-09-23

  A 2024 Nature Communications study links acetylation-dependent control of the spliceosome core protein SmD2 to BRCA1/FANC cassette-exon regulation and PARP inhibitor sensitivity in hepatocellular carcinoma. The findings suggest a preclinical strategy combining HDAC inhibition with PARP inhibition, while leaving clinical benefit and transferability to other tumor types unresolved.

• Tofacitinib citrate: Reliable Cell Assays

  2026-09-23

  This scenario-based guide explains how Tofacitinib citrate (CP-690550 citrate), SKU A4135, can improve the interpretation of viability, proliferation, and inflammatory-cell assays. It combines formulation guidance with concentration-specific evidence from JAK inhibitor research, including important limitations in endothelial models.

• JAK Inhibitors and Endothelial Vascular Effects

  2026-09-22

  This study compares six JAK inhibitors in cytokine-stressed human vascular endothelial cells and shows that reducing IL-6 does not necessarily normalize adhesion, coagulation, or cell-survival responses. Its concentration-dependent findings provide a useful framework for interpreting vascular effects in JAK-STAT and inflammatory disease research.

• Tetrahydromagnolol for Mechanism-Led GPCR Assays

  2026-09-22

  Tetrahydromagnolol is a selective peripheral CB2 receptor agonist with complementary GPR55 antagonist activity. This article develops a mechanism-led assay framework connecting cannabinoid receptor research with lessons from the TBXA2R–ERM metastasis study while separating established pharmacology from testable hypotheses.

• Annexin V-Cy5: Reading Microglial Stress Correctly

  2026-09-21

  A mechanistic guide to using Annexin V-Cy5 apoptosis detection to distinguish microglial cell death from reversible lysosomal dysfunction, with practical workflow guidance for microscopy, flow cytometry, and translational research.

3718 records 3/248 page Previous Next 12345 下5页 Last page